Evidence map›Paper›PMID 42839150›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

A novel oxidative-inflammatory biomarker for Parkinson's disease: clinical utility of the uric acid-to-albumin ratio.

Wenbo Xiu, Gao Zhang, Yang Chen, Chaonan Sun, Yanping Gao, An Li, Haiping Zhang, Ping Shuai, Jing Cheng, Jinxia Wang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenbo XiuTranslational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.ORCID http://orcid.org/0009-0008-5833-910X
Gao ZhangTranslational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yang ChenTranslational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Chaonan SunTranslational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yanping GaoTranslational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
An LiTranslational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Haiping ZhangSichuan Provincial People's Hospital, School of Medicine, Sichuan Provincial Center for Mental Health, University of Electronic Science and Technology of China, Chengdu, China.
Ping ShuaiHealth Management Center & Health Management Research Institute, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Jing ChengTranslational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Jinxia WangTranslational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xiao XiaoTranslational Clinical Immunology Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. ken_023@126.com.
Bolin DengDepartment of Ophthalmology, Sichuan Provincial People' s Hospital, University of Electronic Science and Technology of China, Chengdu, China. 396665760@qq.com.

Funding

Chengdu Municipal Science and Technology Program 2024-YF05-01741-SN,LCMYZHYX-KFKT202302Open Project of Sichuan Provincial Key Laboratory for Clinical Immunology Trans-lational Medicine LCMYZHYX-KFKT202302Provincial Cadre Healthcare Committee Dissemination Grant chuanganyan2024-218Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital 2022QN49Sichuan Medical and Health Promotion Association KY2022SJ0199
6 · The paper itself

Abstract

backgroundEmerging evidence highlights the contribution of systemic inflammation and oxidative stress to the pathogenesis and progression of Parkinson's disease (PD). Accordingly, blood-based biomarkers that capture these processes are of increasing clinical interest. This study evaluated the association between PD and serum uric acid, serum albumin, and their integrated index-the uric acid-to-albumin ratio (UAR)-to determine their potential utility as biomarkers of systemic inflammation, oxidative stress, and disease progression.

methodsA total of 153 patients with PD and 291 healthy controls were included. Serum uric acid, albumin, and UAR were measured through standardized biochemical assays. Group comparisons and multivariable logistic regression were performed to assess associations with PD, and analyses stratified by Hoehn and Yahr stage examined relationships with disease severity.

resultsUric acid, albumin, and UAR levels were significantly lower in patients with PD compared with healthy controls (all p < 0.001). After adjustment for age, sex, hypertension, and diabetes, UAR remained independently associated with PD, with lower UAR corresponding to higher odds of disease (OR = 0.72, 95% CI: 0.63-0.82, p < 0.001). Stratified analyses showed that UAR reductions were most prominent in early and middle PD stages, whereas advanced-stage values approximated those of controls. ROC analysis demonstrated moderate discriminative ability of UAR for PD overall (AUC = 0.630) and for early-to-middle stage disease (AUC = 0.620 and 0.644, respectively).

conclusionUAR is significantly reduced in PD and associated with early-middle disease stages, supporting its potential as an accessible biomarker for PD monitoring, though larger longitudinal studies are needed for validation.

Indexed as

InflammationOxidative StressParkinson DiseaseSerum AlbuminUric AcidAgedBiomarkersDisease ProgressionFemaleHumansMaleMiddle AgedSeverity of Illness IndexBiomarkersSerum AlbuminUric AcidalbuminParkinson’s diseaseuric acidUric acid-to-albumin ratio

Identifiers

PMID42839150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.